

TORCILIN

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory.

Abbreviated Prescribing information for TORCILIN (Cilnidipine 5 mg and 10 mg Tablets)
[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: Cilnidipine is the novel calcium antagonist. It blocks the influx of Ca^{2+} ions into both vascular smooth muscle at the level of L-type Ca^{2+} channels and neuronal cells at the level of N-type Ca^{2+} channels. The L-type Ca^{2+} channel blockade by cilnidipine affects predominantly vascular smooth muscle, thereby producing vasodilation of peripheral resistance vessels and coronary arteries. **INDICATIONS:** It is used for the treatment of mild to moderate hypertension. **DOSAGE AND ADMINISTRATION:** Adult: 5-10 mg once daily, increase to 20 mg once daily if necessary. Cilnidipine usually administered orally after breakfast. **CONTRAINDICATIONS:** Cilnidipine should not be administered in pregnant women and women suspected of being pregnant. Cardiogenic shock, recent MI or acute unstable angina and severe aortic stenosis. Cilnidipine should carefully administration in blood concentration raises patients with severe hepatic dysfunction and history of adverse reactions suffered from calcium antagonist. If administration of calcium antagonists suddenly stop, the patients develop the symptoms have been reported. **PRECAUTIONS:** Sudden withdrawal may exacerbate angina. Discontinue in patients who experience ischemic pain, hypotension, poor cardiac reserve and heart failure following administration. Patient may feel dizziness due to decrease the pressure. So, do not work at height, drive a car or operate heavy machinery while taking this medicine. An ingredient in grapefruit juice may intensify the medicine's effect.

DRUG INTERACTIONS: Other antihypertensives and antipsychotics that cause hypotension may modify insulin and glucose responses. Quinidine, carbamazepine, phenytoin, rifampicin, cimetidine and erythromycin are also interacted with the Cilnidipine. **ADVERSE REACTIONS:** Desquamation, hair loss, hives, pruritus, erythema multiforme, papule, rash, cutaneous dryness, drying periocular, stiff neck, stiffness of muscle, cool feeling, disorientation, headache, sluggishness, difficulty walking, vertigo, lightheadedness, sense to hand vibration, eye abnormalities, hyperemia, irritation of eyes, reduced sense of taste and dysgeusia, vaguely, somnolence, forget things, insomnia, gastritis, gastric ulcer, gastrointestinal hemorrhage, nausea, vomiting, diarrhea, stomatitis, dry mouth, gingival hypertrophy, brash, anorexia, stomach discomfort, epigastric pain, constipation, sense of fullness in the abdomen, periodontitis, liver dysfunction, hepatocyte damage, rise of AST, elevation of ALT, increase in serum bilirubin, LDH rise, serum inorganic phosphorus rise and reduction, CPK raise and decline, serum potassium rise and decrease, serum calcium rise, fasting blood glucose level rise, blood sugar levels, serum cholesterol rise, hyperlipidemia, blood uric acid increased, hyponatremia, serum total protein rise, urine sugar positive, triglyceride rise, heart failure, reduction in blood pressure, ST depression, abnormal electrocardiogram, ST segment elevation, CRP rise, cardiothoracic ratio increase, myocardial infarction, heart rate, heart rhythm disorder, atrioventricular block, atrial tachycardia, palpitation, ventricular tachycardia, atrial fibrillation, T-wave inversion, blood vessels (cardiac) failure, facial redness, generalized redness and transient ischemic stroke, respiratory failure, sore throat, throat burning sensation, dyspnea, cough, epistaxis, red blood cell disorder, hemoglobin increase, polycythemia, anemia erythropenia, hematocrit value decrease and increase, white blood cell-reticuloendothelial disorder, eosinophilia, leukopenia, leukocytosis, changes in neutrophil, changes in lymphocyte, platelet-bleeding coagulopathy, thrombocytopenia, blood creatinine increased, renal function deterioration, renal failure, uric

protein rise, urea nitrogen rise, decrease in urinary volume, frequent urination, urinary sediment (red blood cells) and urine sediment (white blood cell).

MARKETED BY:



TORRENT PHARMACEUTICALS LTD.

Torrent House, Off Ashram Road,
Ahmedabad-380 009, INDIA

IN/ TORCILIN 5, 10 mg /Oct-2015/01/AbPI
(Additional information is available on request)